| Name | Title | Contact Details |
|---|---|---|
Matt Berkle |
Head of U.S. Compliance | Profile |
Volpara Health Technologies Limited is a leading provider of breast imaging analytics and analysis products that improve clinical decision-making and the early detection of breast cancer. Every day, Volpara software helps clinicians better understand their patients and administrators better understand their practices. Volpara Health Technologies Limited (formerly Matakina Technology Limited) is a research, development, and manufacturing company based in Wellington, New Zealand. With a diverse research team led by internationally recognized experts in medical physics, as well as proprietary medical imaging technology covered by multiple patents and trademarks, we apply science to the solving of clinical problems around the world. Volpara Health Technologies Limited holds certification to ISO13485 and is a US FDA–registered establishment whose products are listed accordingly. In addition, our products hold CE Marking under European Medical Device Directive 93/42/EEC. Volpara Solutions Limited is our wholly owned sales and marketing subsidiary.
HistoRX is a Branford, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Pyramid Medical is a Los Alamitos, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
D.M.I. Medical is a Hollywood, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
HeartBeam, Inc. (NASDAQ: BEAT) is a development stage digital healthcare company with proprietary ECG telemedicine technology that will redefine the way high risk cardiovascular patients are diagnosed in an ambulatory setting at any time and any place. Its breakthrough solution employs a reusable, credit card sized, 3D vector ECG recording device and cloud-based software capable of assisting a physician in diagnosing a wide range of cardiovascular disease. HeartBeam is initially focusing on a huge unmet need of helping diagnose heart attacks in patients outside of a medical institution. No single lead ECG technology can offer this value to patients and their physicians. This underserved market is several times larger than the cardiac arrhythmia detection market based on the prevalence of patients with coronary artery disease at high risk of heart attack